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Abstract 
 
NUCLEOPHOSMIN1 (NPM1) is the most frequently mutated gene in acute myeloid leukemia. 
Notably, NPM1 mutations are always accompanied by additional mutations such as those in cohesin 
genes RAD21, SMC1A, SMC3, STAG2 but not in the cohesin regulator NIPBL. In this work, we 
analyze a cohort of adult patients with acute myeloid leukemia and NPM1 mutation and we observe 
specific reduction in the expression of NIPBL but not in other cohesin genes. In our zebrafish 
model, the overexpression of the mutated form of NPM1 also induced the down-regulation of 
nipblb, the zebrafish orthologue of the human NIPBL. To investigate the hematopoietic phenotype 
and the interaction between mutated NPM1 and nipblb, we generate a zebrafish model with nipblb 
down-regulation that shows an increased number of myeloid progenitors. This phenotype is due to a 
hyper activation of the canonical Wnt pathway: the rescue of myeloid cells blocked in an 
undifferentiated state is possible when the Wnt pathway is inhibited by ddk1b mRNA injection or 
indomethacin administration. Our results reveal for the first time a role for NIPBL during zebrafish 
hematopoiesis and suggest that NIPBL/NPM1 interplay may regulate myeloid differentiation in 
zebrafish and humans through the canonical Wnt pathway and that dysregulation of these 
interactions may drive to leukemic transformations. 
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Introduction 
 
Acute Myeloid Leukemia (AML) is a hematologic aggressive malignancy of bone marrow 
characterized by the accumulation of immature myeloid blasts defective in their differentiation and 
function.1,2 The advances in cancer genomics results in the identification of relatively few recurrent 
somatic mutations giving rise to human AML, with an average of 5 mutations in each case of de 
novo AML.3 These somatic mutations, that collectively determine the malignant phenotype, are 
serially acquired in clones of self-renewing hematopoietic stem cells (HSCs), termed pre-leukemic 
HSCs.4 The gene mutated in HSCs that are relevant for AML pathogenesis have been divided in 
nine categories, including transcription-factor fusions, NUCLEOPHOSMIN (NPM1), tumor-
suppressor genes, DNA-methylation–related genes, signaling genes, chromatin modifying genes, 
myeloid transcription-factor genes, cohesin-complex genes and spliceosome-complex genes.5  
NPM1, the most frequently mutated gene in AML, is a phosphoprotein that normally resides into 
the nucleolus.6,7 More than fifty different reported human mutations in NPM1, result in aberrant 
cytoplasmic translocation of the protein, named NPMc+, that functions as an oncogene in vitro8 and 
has a role in aberrant hematopoiesis in vivo. Indeed, murine models expressing NPMc+ in the 
hematopoietic lineage develop myeloproliferative disease9 and leukemia10,11 while the forced 
expression of human NPMc+ in zebrafish causes an increase in primitive early myeloid cells and 
definitive hematopoietic stem cells (HSCs).12,13 It has also been demonstrated, with similar results 
in zebrafish and human AML blasts, that the expression of NPMc+ activates canonical Wnt 
signaling providing insight into the molecular pathogenesis of AML bearing NPM1 mutations.12 
Indeed, the canonical Wnt/β-catenin pathway has been shown to be crucial for the regulation of 
HSCs proliferation, differentiation and apoptosis.14  
Recently, it has been found a strong correlation between mutations in cohesin genes and NPM1 
mutations but they seem to not affect AML patient prognosis.15 The cohesin complex is composed 
by different proteins that form a complex (SMC1, SMC3, RAD21, STAG1 and STAG2), and by 
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additional regulator proteins (NIPBL, MAU2, ESCO1, ESCO2 and HDAC8). This multifunctional 
complex regulates the cohesion of sister chromatids during cell division, but also gene transcription 
and chromatin architecture. Recently, the genes of the cohesin complex have been found mutated in 
almost 10% of patients with myeloid malignancies, while in an additional 15% of patients has been 
found a reduced expression of cohesin transcripts, suggesting a role for the cohesin-complex in the 
pathogenesis of AML.5 In the patient cohort of Thota and colleagues 15, the most frequently mutated 
genes of the cohesin complex are STAG2 (5.9%), RAD21 (2%), and SMC3 (2%), whereas mutations 
in the other cohesins are less than 1%. Somatic mutations in cohesin subunits are mutually 
exclusive and result in predicted loss-of-function phenotype being mainly nonsense and frameshift 
mutations.16 It is to note that in AML neoplasms but not in other kind of tumors17, cohesin 
mutations are associated with a normal karyotype in malignant cells, therefore the role for cohesins 
in the tumor development is not correlated with their function in sister chromatid cohesion rather 
than with their role in mediating DNA accessibility to gene regulatory elements.15 Indeed, in vitro 
and in vivo models for cohesin haploinsufficiency display a delay in the differentiation of HSCs that 
are expanded in an immature state18–21. 
In this work, we have studied the expression of cohesin genes in a cohort of adult AML patients and 
found a specific down-regulation of NIPBL when NPM1 is mutated. Interestingly, we found that 
also in our zebrafish model for NPMc+ expression, nipblb was down-regulated. The zebrafish 
(Danio rerio) is a powerful model to study hematological diseases as it shares several hematopoietic 
genes with higher vertebrates, and mutations in human leukemia causative genes disrupt normal 
hematopoiesis in zebrafish, suggesting a functional conservation during evolution. Our zebrafish 
model with nipblb-loss-of-function showed dysregulation of myeloid cell differentiation with 
increased number of myeloid precursors and a decrease in myeloid mature cells. The hematopoietic 
phenotype presented by nipblb-loss-of-function zebrafish embryos recapitulated the myeloid defects 
presented by embryos with NPMc+ overexpression and it was due to the hyper activation of the 
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canonical Wnt pathway. Indeed, the overexpression of the dkk1b Wnt inhibitor or by indomethacin 
treatment rescued the phenotype. 
Our study provides new insights into the molecular mechanisms underlying NIPBL function, 
identifying the canonical Wnt pathway as one of its target and indicating it as a player with NPMc+ 
in AML development. Using the well-suited zebrafish model, we established a platform to further 
investigate the mechanisms through which NPMc+ and NIPBL might interact and contribute to 
leukemic transformation. 
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Methods  
 
Patients 
Bone Marrow (BM) diagnosis material of N=40 consecutive adult patients affected by AML or 
healthy subjects were collected and characterized as described in Supplementary Methods. Patient’s 
material has been collected after obtaining Informed Consent ASG-MA-052A approved on May 8th 
2012 by Azienda San Gerardo (ASG).  Clinical features have been reported in Supplementary Table 
S1. Human material and derived data has been used in accordance with the Declaration of Helsinki. 
 
Animals 
Zebrafish (Danio rerio) embryos were raised and maintained according to international (EU 
Directive 2010/63/EU) and national guidelines (Italian decree 4th March 2014, n.26) on the 
protection of animals used for scientific purposes as described in Supplementary Methods.  
 
Reverse transcription-PCR and real-time quantitative-PCR assays  
Human and zebrafish embryos RNA extraction was performed using TRIZOL reagents (Life 
Technologies, Carlsbad, CA, USA), following the manufacturer’s protocol. Quantitative RT-PCR 
experiments on human samples were performed with Universal Probe Library system (Roche 
Diagnostics, Basel, Swiss) as described in Supplementary Methods. Primers and probes are reported 
in Supplementary Table S2.  
 
Western Blotting 
Protein extracts were prepared, quantified and loaded as described in Supplementary Methods.  
Antibodies were listed in Supplementary Table S3. Imaging acquisition has been done with the 
Alliance MINI HD9 AUTO Western Blot Imaging System (UVItec Limited, Cambridge) and 
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analyzed with the related software. 
 
In situ hybridization and immunofluorescent analyses. 
Whole mount in situ hybridization (WISH) experiments, were carried out as described by Thisse 
and colleagues22 and in Supplementary Methods. Picture were acquired with the photo camera 
Leica DFC480 (Leica, Wetzlar, Germany). Immunostaining was performed as described23. 
Antibodies list in Supplementary Table S3. Images were acquired as described in Supplementary 
Methods.  
 
Sudan Black staining 
Sudan Black staining was performed as described in24  and in Supplementary Methods. 
 
FACS analyses 
Embryo dissociation was performed as described in25. FACS analysis were performed as described 
in Supplementary Methods from Tg(CD41:EGFP) zebrafish embryos at 3 dpf or Pu.1 stained cells 
derived from embryos at 3 dpf.  
 
Injections and indomethacin treatment 
Injections were carried out on 1- to 2-cell stage embryos. Morpholinos were injected as described in 
Supplementary Methods. Human NPM1 and NPMc+ and zebrafish dkk1b mRNAs were generated 
as previously described12 and injected as described in Supplementary Methods. Indomethacin 
(indomethacin, Sigma-Aldrich) treatment was done as described in.26 
 
Confocal imaging 
Previously immunostained 3 dpf embryos were equilibrated and mounted in 85% glycerol solution 
in PBS and imaged using a “TCS-SP2” confocal microscope (Leica), with 40X oil immersion 
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objective, 488 nm argon ion and 405 nm diode lasers. For each sample, single stack images were 
acquired. 
 
Statistical analyses 
For RT-qPCR experiments, data were statistically analyzed applying one-way ANOVA- or t-tests, 
setting p≤0.05 (*), p≤0.01 (**), and p≤0,001 (***) as significant.27 Data were analyzed using the 
comparative ΔΔCt method both t test and SD values refer to samples triplicates. In zebrafish at least 
three different experiments were done for each analysis. For cell count and phenotypical analyses, 
statistical analysis was performed by Chi square test, with Yates correction when needed. 
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Results 
Cohesin expression in subgroups of adult AML patients carrying mutation in NPM1 and in a 
zebrafish model of NPMc+ expression. 
Recently it has been reported that somatic mutations in cohesin genes are frequently associated with 
NPM1 mutations28, but not with other common AML mutations; however, the expression levels of 
cohesins has never been analyzed. Therefore, we decided to investigate the presence of alterations 
in the expression of cohesin genes in a cohort of N=40 adult AML patients stratified into two 
homogeneous molecular subgroups according to the absence or presence of NPM1 mutation 
(NPMc+). Each subgroup was analyzed by means of RT-qPCR analyses for the expression of the 
cohesin genes: SMC1A, SMC3, NIPBL and RAD21(Figure 1A-D). Interestingly, only NIPBL 
showed a significant decreased expression in AML patients carrying NPM1 mutation (Figure 1B). 
Conversely, when the same patients were divided into subgroups depending on the 
presence/absence of FLT3/ITD mutation, none of the cohesin gene analyzed was differently 
expressed between the two subgroups (Suppl. Figure S1).  
We further analyzed by RT-qPCR the expression of cohesin genes in a zebrafish model with human 
NPMc+ overexpression, previously generated and well characterized12,13. The injection of 100 
pg/embryo of NPMc+ transcript in zebrafish embryos, led to a significant down-regulation of nipblb 
in the whole embryo at 3 dpf, while the expression of other cohesin genes analyzed was unaltered or 
even increased (Figure 1E). We performed a stage-dependent analysis to dissect at which 
developmental stage the overexpression of NPMc+ started to down-regulate nipblb expression in 
the whole embryo. We observed a significant decrease of nipblb expression starting from 48 hpf, 
while no decrease between controls and NPMc+ mRNA injected embryos were observed at 24 and 
36 hpf (Figure 1F). To further verify that the down-regulation of zebrafish nipblb was strictly 
dependent to the forced expression of NPMc+, we injected different doses of the NPMc+ transcript 
(25 pg/embryo, 75 pg/embryo and 125 pg/embryo) and we showed a significant inverse correlation 
between nipblb reduced expression and NPMc+ increase (Figure 1G). Moreover, by Western blot 
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analyses on embryos at 3 dpf, we confirmed that at the dose of 100pg/embryo, the injection of 
NPMc+ mRNA determined a reduction of the Nipbl protein in comparison to control injected 
controls (Figure 1H). 
 
nipblb-loss-of-function and NPMc+ overexpression generates hematopoietic defects in zebrafish 
embryos. 
Since NIPBL is down-regulated in AML patients in association with NPM1 mutation, we wonder 
whether nipblb knock-down might generate defects in myeloid cells differentiation. To investigate 
this hypothesis, we performed the down-regulation of nipblb in zebrafish by injecting a nipblb 
antisense oligonucleotide morpholino targeting the ATG region (nipblb-MO), as previously 
described for the knock-down of Nipbl protein29,30. In AML patients the HSCs and immature 
myeloid blasts are increased. Therefore, to screen for myeloid defects resembling AML patient 
conditions, we analyzed the same cell populations in nipblb-MO injected embryos. Knock-down of 
nipblb did not lead to significant differences in the HSCs, as shown by confocal images of the 
Caudal Hematopoietic Tissues (CHT) of Tg(CD41:GFP) embryos31 at 3 dpf (Figure 2A-C) and by 
cytofluorimetric analyses (FACS) to quantify the CD41:GFPlow HSCs cells in comparison to 
controls (Figure 2G). On the other hand, at the same stage, nipblb-MO injected embryos showed an 
increase of myeloid progenitors, positive for the Pu.1 antibody (Figure 2H-I; FACS in K-L-N). 
These observations were also confirmed by means of Whole Mount in situ-hybridization (WISH) 
techniques with the HSC marker cmyb and the myeloid progenitor marker spi1b with relative 
quantifications of the observed phenotypes, and RT-qPCR analyses (Suppl. Figure S2). Moreover, 
to verify if the increased myeloid cells were blocked in an undifferentiated state, we performed a 
Sudan black staining to visualize mature myeloid cells24. At 4 dpf we observed a reduction of 
neutrophils (Figure 2O-P).  
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It has been previously reported that the forced expression of human NPMc+ in zebrafish embryos 
increased HSCs population at 30-36 hpf13. To further analyze whether the hematopoietic defects are 
still present later during hematopoiesis and are extended to myeloid cells, we injected the embryos 
with NPMc+ mRNA (100 pg/embryo) and analyze the hematopoietic phenotype. The CD41:GFPlow                     
cells in the CHT of NPMc+-injected embryos were expanded in comparison to controls (Figure 2A-
C; FACS in D-F-G), as well as the Pu.1 positive myeloid precursors (Figure 2H-J; FACS in K-M-
N). Sudan black staining visualized a decrease in mature myeloid cells in NPMc+ injected embryos 
in comparison to controls (Figure 2O-Q). Moreover, the expression levels of cmyb and spi1b were 
tested also by WISH and RT-qPCR techniques which corroborated our previous findings (Suppl. 
Figure S3). 
To confirm the specificity of the hematopoietic defects obtained with nipblb-MO injection, we used 
a second morpholino targeting the 5’UTR region of nipblb (5’UTRnipblb-MO), previously used 
and validated29. The injection of this second morpholino reduced the Nipbl protein levels as 
observed by Western blot analyses, confirming its efficacy in blocking protein production. It also 
recapitulated the hematopoietic defects observed with the injection of the ATG morpholino, 
showing an increased number of myeloid precursors positive for spi1b and a decreased number of 
mature myeloid cells. Moreover, when co-injected at subcritical doses, the two nipblb-MOs 
cooperated to induce the myeloid phenotype (Suppl. Figure S4). 
 
Nipbl downregulation and NPMc+ overexpression both induce the hyper activation of the 
canonical Wnt pathway  
Previous experimental and clinical evidences suggested a close correlation between AML 
development and canonical Wnt pathway dysregulation, especially in patients with NPM1 
mutation12. To examine whether nipblb and NPMc+ regulate the activation status of canonical Wnt 
pathway, we used the Tg(TOPdGFP) transgenic line that bears the GFP reporter gene under the 
control of four enhancers and the basal promoter of lef1, a β-catenin dependent transcription 
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factor32. Tg(TOPdGFP) embryos were injected with nipblb-MO or NPMc+ mRNA and the 
expression of gfp and axin2, one of the direct targets of activated β-catenin, were analysed by RT-
qPCR at 3 dpf33. Both genes were upregulated following both nipblb knock-down or NPMc+ 
overexpression, indicating a hyper activation of the canonical Wnt pathway (Figure 3A-B). To 
determine whether the Wnt signaling was enhanced specifically in hematopoietic cells, confocal 
images of the CHT of Tg(TOPdGFP) embryos were analyzed (Figure 3C). GFP+ cells were 
increased either in nipblb-MO and NPMc+ injected embryos (10 increased/10 scored). Specifically, 
nipblb down-regulation almost duplicated the number of GFP+ cells in the CHT (N=27+5) in 
comparison to controls (N14+3), (Figure 3D-E, quantification in I). Also NPMc+ overexpression 
increased the number of GFP+ cells in the CHT (N=20+4) in comparison to controls (N=14+3), 
(Figure 3D-G, quantification in I). To further demonstrate that the increase of GFP+ cells in the 
CHT was due to hyper activation of the canonical Wnt pathway, we injected the Wnt inhibitor 
dkk1b mRNA (50 pg/embryo)12. We validated the efficiency of dkk1b mRNA injection as the GFP+ 
cells were diminished or absent in the hindbrain ventricle and in the CHT of the Tg(TOPdGFP) 
embryos in comparison to controls (Suppl. Figure S5). The co-injection of dkk1b in nipblb-MO or 
NPMc+ mRNA injected embryos rescued the number of GFP+ cells in the CHT (10 rescued/10 
scored for both) or even diminished the GFP+ cells (N=8+3 for nipblb-MO/dkk1b; N=10+3 for 
NPMc+/dkk1b) (Figure 3F-H, quantification in I). Moreover, using the Wnt reporter line 
Tg(TOPdGFP) we verified that, following nipbl-MO injection, the canonical Wnt pathway 
appeared downregulated at 24 hpf but was then hyper activated at 48 hpf (Suppl. Figure S6). This 
observation confirmed our previous work on a zebrafish model for nipbl-loss-of-function where we 
observed the dowregulation of the canonical Wnt pathway at 24 hpf and we correlated this with 
neurological defect presented by patients affected by Cornelia de Lange Syndrome (CdLS)30.  
Having seen a hyper activation of the canonical Wnt pathway in our zebrafish model with nipbl 
downregulation, we analyzed it also in AML human patients by measuring the expression of 
AXIN2, previously used as a reporter of canonical Wnt pathway activation in AML patients12. We 
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did not observe a significant increase in AXIN2 expression in our cohort of AML patients with 
NIPBL downregulation (NIPBL<1) in comparison to those with normal or increased expression of 
NIPBL (NIPBL>1) (Suppl. Figure S7). Further analyses in major cohorts will be necessary to 
underline the correlation between NIPBL expression and canonical Wnt pathway. 
 
 
Hyper activation of the canonical Wnt signalling in HSCs cells impairs myeloid differentiation. 
To dissect which hematopoietic cell type in the CHT showed a hyper activation of the canonical 
Wnt pathway following nipblb-MO or NPMc+ mRNA injections, we sorted the CD41:GFPlow cells 
(0.8% ctrl, 1% nipblb-MO, 1.1% NPMc+) from 3 dpf embryos injected with nipblb-MO or NPMc+ 
mRNA and we observed a modest increase in axin2 expression in comparison to CD41:GFPlow cells 
from controls (Figure 4A-A’’’). Moreover, we performed immunofluorescence staining with the 
Active β-catenin (Active β-cat) antibody for the Wnt pathway and GFP antibody for HSCs cells of 
the CD41:GFP embryos. An increased number of double positive cells GFP/Active β-cat was 
present in the CHT of embryos at 3 dpf injected with nipblb-MO or NPMc+ mRNA (5 double 
positive cells indicated by the arrows in the CHT of Figure 4C’’-D’’) in comparison to controls (2 
double positive cells indicated by the arrows in the CHT of Figure 4B’’), demonstrating that the 
Wnt pathway was activated specifically in HSCs cells (Figure 4B-D’’).  
The myeloid differentiation defects presented by nipblb-MO and NPMc+ injected embryos at 3 dpf 
were caused by the hyper activation of the canonical Wnt pathway. In this regard, the inhibition of 
this pathway performed both with dkk1b mRNA injection or by treatment with the Wnt 
pharmacological inhibitor indomethacin,26 rescued the hematopoietic phenotype. Indeed, by WISH 
we showed that the increased number of myeloid precursors positive for spi1b observed in nipblb-
MO or NPMc+ mRNA injected embryos, returned to levels comparable to controls (Figure 5A-G).  
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NPMc+ and nipblb cooperation in the hyper activation of the canonical Wnt signaling and myeloid 
defects 
Our evidences so far showed that NPMc+ down-regulates NIPBL, both in human AML patients and 
in zebrafish. We also demonstrated that dysregulation of both genes impairs myeloid differentiation 
through the hyper activation of the canonical Wnt pathway. To further address a possible 
cooperation between the two genes, we performed dose-response assays. We injected subcritical 
doses of nipblb-MO (0,6 pmol/embryo) or NPMc+ mRNA (50 pg/embryo) that singularly did not 
cause an increased in GFP+ cells in the CHT of Tg(TOPdGFP) embryos or in the spi1b positive 
myeloid progenitors (Figure 6B-D) in comparison to controls (Figure 6A, quantification in E). 
When co-injected, subcritical doses of nipblb-MO/NPMc+ recapitulated the phenotype previously 
observed by means of full doses injections, with an increased number of GFP+ cells in the CHT of 
the Tg(TOPdGFP) embryos and an enhanced expression of spi1b (Figure 6F-I, quantification of the 
phenotypes in J), indicating a cooperation between NPMc+ and nipblb down-regulation. 
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Discussion 
In this work, we rely on the observation that, in addition to the cohesin mutations detected in 10% 
of patients with myeloid malignancies, low expression of cohesin genes was present in an additional 
15% of patients showing similar expression signatures as those with somatic cohesin mutations28. 
Therefore, we investigated the expression of cohesin genes in our cohort of 40 adult AML patients 
divided for the absence/presence of NPM1 mutation. We chose to analyze NPM1 mutations as they 
are pivotal in AML but likely insufficient by their self to cause malignant transformation, requiring 
the co-occurrence of other mutations such as FLT3-ITD or RAS9,34. In addition, it has been already 
reported a correlation between NPM1 mutations and somatic mutations in cohesin genes,28 but the 
specific loss-of-function of cohesins has never been investigated in association with NPM1 
mutations. Among the cohesin genes analyzed in our AML adult patient cohort, we found that only 
NIPBL showed a lower expression when NPM1 was mutated. NIPBL is a regulator of the cohesin 
complex deputed to the loading of the complex onto the double-strand DNA. However, previous 
studies suggested a specific activity of NIPBL in gene transcription regulation and NIPBL binding 
sites, which do not overlap with those of cohesins, were in vitro identified.35 Therefore, we decided 
to analyzed the effects of NIPBL down-regulation on myeloid differentiation. Zebrafish represents 
an ideal model for the study of cohesin genes function as it is possible to generate knock-down with 
the injection of specific oligonucleotide antisense morpholino.30 Therefore, we investigate the 
effects of nipblb-loss-of-function during zebrafish definitive hematopoiesis and we observed an 
increased number of myeloid progenitors. Similar results have been obtained in different models of 
cohesins loss-of-function. For example, in murine models the use of shRNAs against Stag2 and 
Smc3 generated a maturation block, delayed differentiation, and enhanced renewal of HSCs, similar 
to myeloid neoplasms.36 In another work, RNAi mouse models have created with inducible knock-
down of Rad21, Smc1a and Stag2 leading to a shift in the hematopoietic stem compartment, an 
increased replating capacity and, over time, the development of clinical features of 
17 
 
myeloproliferative neoplasms.18 NIPBL is not a recurrently mutated gene in AML such as STAG2, 
SMC3, SMC1A, and RAD21.28 In humans, heterozygous loss-of-function mutations of NIPBL cause 
the Cornelia de Lange Syndrome (CdLS).37 Nevertheless, CdLS patients with mutations in NIPBL 
or in other cohesin genes are not predisposed to myeloid neoplasms. Rare cases of leukemia have 
been reported in CdLS probably caused by other physiological aspects of the pathology.38–40 The 
mutations in cohesin genes responsible for CdLS and leukemia insurgence are considered different 
for their physio-pathological output: cohesin mutations in tumors occur in somatic an adult cells 
while germline cohesin mutations in CdLS patients occur in an embryonic tissue. Moreover, 
cohesin mutations in cancer might not trigger, but contribute to tumorigenesis only with other 
mutations such as TET241, NPM19,42, DNMT3A43 or FLT3-ITD44. As a matter of fact, we speculate 
that the decrease in NIPBL expression observed in AML patients, might not be due to specific 
somatic mutations occurred at the gene level, rather than a secondary effect caused by genetic 
lesions arisen elsewhere (i.e. NPM1). 
In nipblb-loss-of-function embryos we observed defects in myeloid differentiation with increased 
number of myeloid progenitors and decreased myeloid mature cells. These hematopoietic defects 
share similarities with the myeloproliferative phenotype of NPMc+ embryos12,13. Indeed, we also 
confirmed that the forced expression of NPMc+ generated a phenotype with an expansion of HSCs 
and myeloid precursors. However, the main difference in the hematopoietic phenotype generated by 
nipblb knock-down and NPMc+ forced expression, was in the HSCs population. In this regard, 
while in NPMc+ embryos the HSCs were significantly increased, in nipblb-MO injected embryos 
they were almost comparable to controls. This result is not surprising as we demonstrated that 
nipblb acts downstream of, and is regulated by, NPMc+. Therefore, it is conceivable that, also in the 
hematopoietic cascade that drives to myeloid differentiation, the effects of nipblb are directed on a 
population that derived from HSCs, such as myeloid progenitors.  
We further observed that in nipblb knock-down and NPMc+ overexpressed zebrafish embryos, the 
Wnt/β-catenin pathway was hyper activated. In the hematopoietic process many signaling pathways 
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are critical during different developmental stages of HSCs and for their maturation into 
differentiated lineages. In particular, the canonical Wnt pathway exerts its action on specific cell 
populations being fine-tuned in a dosage-dependent fashion45. We demonstrated that Nipbl is an 
active player in this modulation. Indeed, in a previous work, we showed that the downregulation of 
nipblb in zebrafish embryos at 24 hpf, caused a decreased activation of the canonical Wnt 
pathway30. In this work we demonstrated that, from 48 hpf, Nipbl acts in an opposite way by hyper 
activating the Wnt pathway in the whole embryo. It is conceivable that, given its double effects of 
on Wnt pathway, Nipblb might be considered a new player for canonical Wnt pathway modulation. 
Recently several Wnt inhibitors have been identified as potential drugs to reduced tumor cell 
viability in lymphoma and myeloma cell lines in vitro and in vivo46. Thus, Wnt/β-catenin inhibitors, 
such as indomethacin that is already used in clinical trials26 and is effective also in our study for the 
rescue of the hematopoietic phenotype, could be an attractive candidates for the development of 
new therapeutic treatments for NPMc+ AML patients.  
Further analyses are necessary to investigate the mechanisms through which NPMc+ interact with 
NIPBL and they regulate the canonical Wnt pathway and the hematopoietic phenotype. One 
hypothesis that raised by previous and our analyses is the involvement of other members of the 
cohesin complex such as Rad21 that is negatively regulated by Nipbl both in murine fibroblast47 
and zebrafish (see Figure 1F). Alternatively, the aberrant cytoplasmic dislocation of mutant NPM1 
might alter the normal regulation of NIPBL expression in the nucleus, similarly to what happens in 
the important PU.1-NPM1 mediated regulation in myeloid precursors48. Large scale transcriptomic 
and/or proteomic analyses will be useful to unravel the mechanism and, at this purpose, the use of 
the zebrafish platform with cohesin knock-down might be a suitable model system.  
In conclusion, our study correlates for the first time NIPBL with NMP1 mutations in adult AML 
patients and demonstrates their interplay in myeloid cell differentiation in zebrafish throughout an 
involvement of the canonical Wnt pathway. The results obtained will foster the identification of 
new potential targets for treatments of AML subgroups.  
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Figure Legends 
 
Figure 1: Expression analyses of cohesin genes in AML adult patient Bone Marrow samples 
divided in two subgroups for the absence/presence of NPM1 mutations and in a zebrafish 
model for NPM1 mutation (NPMc+). (A-D) RT-qPCR analyses in N=40 AML adult patients 
indicated that the expression of NIPBL was decreased when NPM1 was mutated. The other cohesin 
genes analyzed did not present a correlation with the presence of NPM1 mutations. (E) RT-qPCR 
analyses of cohesin genes expression in a zebrafish model with overexpression of human NPMc+, 
showed that nipblb was down-regulated in comparison to controls at 3 dpf. (F) RT-qPCR time 
course analyses at 24, 36 and 48 hpf of nipblb expression in embryos injected with NPMc+ 
transcript. nipblb was significantly down-regulated at 48 hpf. (G) RT-qPCR analyses of nipblb 
expression in zebrafish embryos at 3 dpf overexpressed with different doses of human NPMc+. The 
down-regulation of nipblb was significantly dependent to the NPMc+ injection doses. (H) Western 
blot analyses of Nipbl protein expression in embryos at 3 dpf injected with 100 pg/ embryo of 
NPMc+ transcript. Vinculin marker was used for normalization. Western blot images were 
processed as described in Supplementary Methods. Asterisks represent *= p<0.05, **= p<0.01 and 
***=p<0.001 (B, E, F, G, H). ns: non-significant; AML: Acute Myeloid Leukemia; MO: 
morpholino; RT: Retro Transcription. 
 
 
Figure 2: Myeloid cell differentiation is affected in nipblb-MO and NPMc+ mRNA injected  
embryos. (A, B, C) Confocal analyses of CD41:EGFP HSCs of controls, nipblb-MO and NPMc+ 
mRNA injected embryos at 3 dpf. The GFP positive HSCs cells were slightly increased in nipblb-
MO, but significantly increased in NPMc+ embryos in comparison to controls. (D-G) FACS 
analyses on GFPlow HSCs positive cells. (H, I, J) Confocal analyses of Pu.1 positive myeloid 
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precursor cells of controls, nipblb-MO and NPMc+ mRNA injected embryos at 3 dpf. The GFP 
positive myeloid precursors cells were increased in both nipblb-MO and NPMc+ embryos in 
comparison to controls. (K-N) FACS analyses on Pu.1 GFP positive cells. (O-Q) Sudan black 
staining for mature myeloid cells on controls, nipblb-MO and NPMc+ mRNA injected embryos at 4 
dpf. The mature myeloid cells were diminished in both nipblb-MO and NPMc+ embryos in 
comparison to controls. Images were processed as described in Supplementary Methods. Scale bar 
represents 100 μm. Asterisks in (G) represent ***=p<0.001. ns: non-significant; HSCs: 
Hematopoietic Stem Cells; FACS: Fluorescence-Activated Cell Sorting; MO: morpholino; GFP: 
Green Fluorescent Protein; CHT: Caudal Hematopoietic Tissue. 
 
 
Figure 3: Canonical Wnt signaling is hyper activated in nipblb-MO and NPMc+ 
Tg(TOPdGFP) injected embryos at 3 dpf. (A, B) RT-qPCR analyses of gfp and axin2 expression 
in nipblb-MO and NPMc+ Tg(TOPdGFP) injected embryos indicated an increase of canonical Wnt 
activation status in comparison to controls. (C) Scheme of trunk-tail region of embryos. Confocal 
images were always performed in the same embryo region, comprising the tip of the yolk sack 
extension (YSE) between the dorsal aorta (DA, red line) and the vein (V, blue line) as indicated by 
pink brackets. (D-H) Confocal images of the CHT of Tg(TOPdGFP) embryos injected with nipblb-
MO (E) and NPMc+ (G) showed an increase of GFP+ cells in comparison to controls (D). The co-
injection of the Wnt inhibitor dkk1b mRNA rescued the number of GFP+ cells (F-H). (I) 
Quantification of GFP+ cells in the selected region of the CHT. Images were processed as described 
in Supplementary Methods. Scale bar represents 100 μm. Asterisks in (A, B, I) represent *=p<0.05, 
**=p<0.01 and ***=p<0.001. ns: non-significant; MO: morpholino; GFP: Green Fluorescent 
Protein; CHT: Caudal Hematopoietic Tissue. 
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Figure 4: Canonical Wnt pathway is hyper-activated specifically in HSCs cells. 
(A-A’’) FACS sorting of CD41:GFPlow cells from controls (A), nipblb-MO (A’) and NPMc+ mRNA 
(A’’) embryos at 3 dpf and RT-qPCR axin2 expression analyses on sorted cells (A’’’). (B-D’’) 
Immunofluorescence staining with GFP for HSCs (B, C, D) and Active β-catenin for Wnt activation 
(Active β-cat) (B’, C’, D’) antibodies. Merge of the two signals (B’’, C’’, D’’) showed an increased 
number of double positive cells GFP/Active β-cat cells (arrows) in the CHT of embryos at 3 dpf 
injected with nipblb-MO or NPMc+ mRNA in comparison to controls. Images were processed as 
described in Supplementary Methods. Scale bar represents 100 μm. Asterisk in (A’’’) represents 
*=p<0.05. ns: non-significant; HSCs: Hematopoietic Stem Cells; FACS: Fluorescence-Activated 
Cell Sorting; MO: morpholino; RT: Retro Transcription; GFP: Green Fluorescent Protein; CHT: 
Caudal Hematopoietic Tissue. 
 
Figure 5: Myeloid cell differentiation impairment in nipblb-MO and NPMc+ injected embryos 
is caused by hyper-activation of the canonical Wnt signaling. (A-G) WISH analyses of spi1b. 
The expression of spi1b was increased in nipblb-MO (B) and NPMc+-injected embryos (E) in 
comparison to controls (A). Rescue of the myeloid phenotype was obtained with the injection of the 
Wnt inhibitor dkk1b mRNA (C; F) and with indomethacin treatment (D; G). Quantifications of the 
observed phenotypes in (H) and (I). Images were processed as described in Supplementary 
Methods. Scale bar represents 100 μm. Asterisks (H and I) represent *=p<0.05 and ***=p<0.001. 
MO: morpholino; WISH: Whole Mount In Situ Hybridization. 
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Figure 6: Co-injection of subcritical doses of nipblb-MO and NPMc+ that singularly do not 
have effects, indicates cooperation between NPMc+ and nipblb in myeloid differentiation. (A-
D) The number of GFP+ cells in the CHT was increased when embryos at 3 dpf were co-injected 
with subcritical doses of nipblb-MO/sub-NPMc+ (D) in comparison to single injection of a 
subcritical dose of controls (A), nipblb-MO (B) and NPMc+ (C). (E) Quantification of GFP+ cells in 
the CHT. (F-I) WISH analyses of the myeloid precursor marker spi1b. spi1b expression was 
increased in embryos co-injected with subcritical doses of nipblb-MO and NPMc+ (I) in 
comparison to the control and sub-nipblb-MO or sub-NPMc+ injected embryos (F-H). (J) 
Quantification of the embryos presenting a spi1b increased expression. Images were processed as 
described in Supplementary Methods. Scale bar represents 100 μm. Asterisks in (E) represent 
***=p<0.001, (J) represent **=p<0.01. MO: morpholino; GFP: Green Fluorescent Protein; CHT: 
Caudal Hematopoietic Tissue; WISH: Whole Mount In Situ Hybridization. 
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Supplementary Methods 
 
Patients 
Patients were previously characterized for specific molecular aberrancies, such as mutations for 
NPM1 and FLT3-ITD, in addition to translocations t(9;22), t(8;21) and inv(16), in accordance to 
specific clinical protocol requirements. Patients enrolled belong to different French–American–
British (FAB) classification systems (FABs), excluding M3, therefore all patients were negative for 
translocation t(15;17). BM of were collected as controls for gene expression assays, upon appropriate 
Informed Consent ASG-MA-052A approved on May 8th 2012 by Azienda San Gerardo (ASG).   
 
Animals 
The fish were maintained under standard conditions in the fish facilities of Bioscience Dept, 
University of Milan, Via Celoria 26 - 20133 Milan, Italy (Aut. Prot, n. 295/2012-A -  20/12/2012); 
and Cogentech s.c.a.r.l. (Aut. Prot. n. 007894 - 29/05/2018), via Adamello 16 - 20139 Milan, Italy).  
We express the embryonic ages in hours post fertilization (hpf) and days post fertilization (dpf). 
Zebrafish AB strains obtained from the Wilson lab (University College London, London, UK) were 
maintained at 28°C on a 14 h light/10 h dark cycle. The zebrafish transgenic TOPdGFP line was 
described previously.1 The zebrafish transgenic CD41:GFP/kdrl:dsRED line was described 
previously.2  Embryos were collected by natural spawning, staged according to Kimmel and 
colleagues,3 and raised at 28°C in fish water (Instant Ocean, 0,1% Methylene Blue) in Petri dishes, 
according to established techniques. After 24 hpf, to prevent pigmentation 0,003% 1-phenyl-2-
thiourea (PTU, Sigma-Aldrich, Saint Louis, MO, USA) was added to the fish water. Embryos were 
washed, dechorionated and anaesthetized, with 0.016% tricaine (Ethyl 3-aminobenzoate 
methanesulfonate salt; Sigma-Aldrich), before observations and picture acquisitions.  
 
 
Reverse transcription-PCR and real-time quantitative-PCR assays  
For human sample RT-qPCR experiments, Superscript II enzyme (Life Technologies) was used for 
cDNA synthesis. For this set of experiments, a Light Cycler 480II (Roche Diagnostics, Basel, Swiss) 
was used. Primers and probes were selected according to the Software Probe Finder (Roche 
Diagnostics) and are reported in Supplementary Table S2. hGUS gene was used as reference and 
healthy patients cells as standard control. After DNase I RNase-free (Roche Diagnostics) treatment 
to avoid possible genomic contamination, 1μg of RNA was reverse-transcribed using the “ImProm-
II™ Reverse Transcription System” (Promega, Madison, Wisconsin USA) and a mixture of oligo(dT) 
and random primers according to manufacturer’s instructions. RT-qPCRs were carried out in a total 
volume of 20 µl containing 1X iQ SYBR Green Super Mix (Promega), using proper amount of the 
RT reaction. RT-qPCRs were performed using the BioRad iCycler iQ Real Time Detection System 
(BioRad, Hercules, CA, USA). For normalization purposes, rpl8 expression levels4 were tested in 
parallel with the gene of interest. Expression levels in the Y axis were relative to the control. 
 
Western Blotting 
At least 30 zebrafish embryos were used for protein preparation and the yolk was previously removed 
from embryos to avoid yolk protein contamination. Protein extracts were classically prepared in RIPA 
buffer (50 mM Tris-HCl pH 7.4, 1% NP-40, 150 mM NaCl, 0.25% sodium deoxycholate, 1mM 
EDTA, 1mM PMSF, protease inhibitors Roche) (2 l/embryo or 1l/ tail).  The protein concentration 
was determined using a Quantum Micro BCA protein assay kit according to the manufacturer's 
instructions (Euroclone, Pero, MI, Italy).  30-40 g of each sample were loaded onto a 7.5% or 10% 
polyacrylamide gels and subjected to electrophoresis. The proteins were then transferred onto PVDF 
membranes which were blocked using a blocking solution at room temperature for 1 hour prior to 
incubation with the primary antibodies: Nipbl (anti rabbit 1:200, Novus Biologicals Littleton, 
Colorado, USA) and Vinculin (anti mouse 1:6000, Sigma-Aldrich). After incubation with the HRP-
conjugated secondary antibodies for 1 h at room temperature (mouse Santa Cruz Biotechnology, 
Dallas, TX, USA, rabbit Thermofisher, Waltham, MS, USA), the protein bands were detected using 
ECL detection systems. Imaging acquisition has been done with the Alliance MINI HD9 AUTO 
Western Blot Imaging System (UVItec Limited, Cambridge) and analyzed with the related software. 
Images were processed using the Adobe Photoshop software and when necessary, different parts of 
the same image have been took separately and later merged in a single image.  
 
In situ hybridization and immunofluorescent analyses. 
For quantification of the observed phenotypes, WISH experiments were done at least in 2 batches of 
embryos (minimum 15-20 embryos for each category). Embryos were fixed overnight in 4% 
paraformaldehyde (Sigma-Aldrich) in Phosphate Buffer Saline (PBS) at 4 °C, then dehydrated 
stepwise to methanol and stored at −20 °C. Antisense riboprobes were previously in vitro labelled 
with modified nucleotides (i.e. digoxigenin, fluorescein, Roche Diagnostics). cmyb and spi1b probes 
have been previously described (myl7, Zebrafish Information Network5). Primary antibody was anti-
GFP (1:1000, Torrey Pines Biolab, Houston, TX, USA), anti Active-cat (Clone 8E7, 1:50 Merck, 
Darmstadt, Germany) and anti PU.1 (1:100, Merck); the secondary antibodies was Alexa 488-
conjugated goat anti-rabbit IgG and Alexa 546-conjugated goat anti-mouse IgG (1:400, Invitrogen 
Life Technologies, Carlsbad, CA, USA). Images were acquired as described in using a microscope 
equipped with a digital camera with LAS Leica imaging software (Leica). Images were processed 
using the Adobe Photoshop software and when necessary, different focal images planes of the same 
image have been took separately and later merged in a single image.  
 
Sudan Black staining 
Embryos were fixed with 4% PFA-PBS for 2 hours at room temperature, rinsed in PBS, incubated in 
Sudan Black (Sigma-Aldrich) for 20 minutes, washed in 70% ethanol in water, then rehydrated to 
PBS+0.1% Tween 20 (PBT). 
 
FACS analyses 
Embryos were anesthetized with 1X Tricaine/E3 and dissociated with 0.25% trypsin-EDTA 
(Ethylenediaminetetraacetic acid) and Collagenase from Clostridium (Sigma-Aldrich C9891) 
100mg/ml (500 µl dissociation mix/tube of embryos) by pipetting. 1 ml of DMEM (Dulbecco's 
modified of Eagle medium)-10% FBS (fetal bovine serum) was added and centrifuged 5’ at 3000 
rpm. Dissociated cells were washed twice in PBS 1X, filtered through 70 µm nylon mesh and 
transferred into a FACS (Fluorescence-activated cell sorting) tube. For Pu.1 staining, cells were 
harvested as described above and incubated for 20’ on ice in PBS 1X and formaldehyde 2%, washed 
in PBS 1X + 1% BSA (bovine serum albumin), resuspended in 100 µl TritonX100 0.1 % in PBS 1X 
and incubated 10’ at room temperature. Then, cells were washed once in PBS 1X + 1% BSA and 
incubated for 45’ at 4°C in BSA 5% in PBS 1X. Cells were spinned-down and the pellet was 
resuspended in 100 µl of anti PU.1 (1:100, Merck) diluted in PBS 1X + 1% BSA and incubated for 1 
hour at room temperature, washed once in PBS 1X + 1% BSA; the secondary antibody was Alexa 
488-conjugated goat anti-rabbit IgG (1:400, Invitrogen Life Technologie) diluted in PBS 1X + 1% 
BSA and incubated for 1 hour at room temperature. The pellet was washed and kept stained at 4°C 
until FACS analysis. 
 
FACS sorting, RNA extraction and cDNA synthesis of GFP low cells 
To sort the low and high GFP positive cells, 40 embryos for control, nipblb-MO and NPMc+ mRNA 
condition were collected and dissociated as in6, suspended in 0.4 ml of PBS and sorted with the 
FACSAria cell sorter. GFP low positive cells were subjected to TRIZOL extraction following 
manufacturer instruction a resuspended in 5 uL of Nuclease free water. Half of the RNA obtained 
was used for retro-transcription using Superscript IV VILO. In retro-transcription procedure, 
EzDNAse digestion step has been included, time of reverse transcription was increased to 30 minutes. 
 
Injections  
Two different morpholino against nipblb: the ATG-nipblb-MO (nipblb-MO) and the 5’UTR-nibpblb-
MO (5UTRnibpblb-MO) were used (Gene Tools LLC, Philomath, OR, USA) both previously 
described and validated.7 nipblb-MO was injected at the concentration of 1 pmol/embryo in 1x 
Danieau buffer (pH 7,6) for full dose experiments, and at a concentration of 0,6 pmol/embryo for 
subcritical doses. 5UTRnibpblb-MO was injected at the concentration of 0,5 pmol/embryo in 1x 
Danieau buffer (pH 7,6) for full dose experiments, and at a concentration of 0,3 pmol/embryo for 
subcritical doses. As a control, we injected a standard control morpholino oligonucleotide (ctrl-MO, 
Gene Tools). Human NPM1 and NPMc+ and zebrafish dkk1b mRNAs were injected at the following 
concentrations: 120 pg/embryo of NPM1 mRNA, 100 pg/embryo of NPMc+ mRNA and 50 
pg/embryo of dkk1b mRNA. For dose-depended assays, NPMc+ mRNA was injected at 25-75 and 
125 pg/embryo. For subcritical doses, NPMc+ was injected at 50 pg/embryo. 
 
Statistical analyses 
For RT-qPCR experiments, data were statistically analyzed applying a two-tailed t-test setting p≤0.05 
(*), p≤0.01 (**), and p≤0,001 (***) as significant.27 Data were analyzed using the comparative ΔΔCt 
method both t test and SD values refer to samples triplicates. In zebrafish at least three different 
experiments were done for each analysis. For cell count and phenotypical analyses, statistical analysis 
was performed by Chi square test, with Yates correction when needed. 
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Supplementary Figure Legends and Tables 
 
Suppl. Figure S1: Expression analyses of cohesin genes in AML adult patient Bone Marrow samples 
divided in two subgroups for the absence/presence of FLT3/ITD mutations. (A-D) RT-qPCR analyses 
in AML adult patients indicated that the expression level of cohesin genes analyzed was not modified 
with FLT3/ITD mutation. ns: non-significant; AML: Acute Myeloid Leukemia, RT: Retro 
Transcription. 
 
 
Suppl. Figure S2: Myeloid cell differentiation is affected in nipblb-loss-of-function embryos. (A-
B, E-F) WISH analyses of cmyb, marker of HSCs and spi1b, marker of myeloid precursors at 3 dpf. 
(A-D) The expression of cmyb was comparable in nipblb-MO-injected embryos (B) and controls (A); 
quantification of the observed phenotypes in (C). RT-qPCR analyses of cmyb expression were 
performed on the tails of the embryos at 3 dpf (D). (E-H) The expression of spi1b was increased in 
nipblb-MO-injected embryos (F) in comparison to controls (E); quantification of the observed 
phenotypes in (G). RT-qPCR analyses of spi1b expression were performed on the tails of the embryos 
at 3 dpf (H). Scale bar represents 100 m. Asterisks in (G and H) represent *=p<0.05. ns: non-
significant; WISH: Whole Mount In Situ Hybridization; MO: morpholino; RT: Retro Transcription. 
 
  Suppl. Figure S3: HSCs and myeloid cell differentiation are affected in NPMc+ injected 
embryos. (A-B) WISH analyses of cmyb, marker of HSCs, (E-F) spi1b, marker of myeloid 
precursors. The expression of cmyb and spi1b were increased in NPMc+-injected embryos (B) and 
(F) in comparison to controls (A) and (E); quantification of the observed phenotypes in (C-G). RT-
qPCR analyses of cmyb expression (D), and spi1b expression (H), were performed on the tails of the 
embryos. Scale bar represents 100 m. Asterisks in (D-H) represents *=p<0.05, in (C) **=p<0.01 
and in (G) ***=p<0.001. WISH: Whole Mount In Situ Hybridization; MO: morpholino; RT: Retro 
Transcription. 
 
 Suppl. Figure S4: Myeloid cell differentiation is affected in 5’UTRnipblb-loss-of-function 
embryos. (A) Western blot analyses, repeated twice, of Nipbl protein expression in embryos at 24 
hpf injected with 5’UTRnipblb-MO. Vinculin marker was used for normalization. (B, C, E, F) WISH 
analyses of cmyb, marker of HSCs (B-C) and spi1b, marker of myeloid precursors (E-F). The 
expression of cmyb was comparable in 5’UTRnipblb-MO-injected embryos (C) and controls (B); 
quantification of the observed phenotypes in (D). The expression of spi1b was increased in 
5’UTRnipblb-MO-injected embryos (F) in comparison to controls (E); quantification of the observed 
phenotypes in (G). (H-I) Sudan black staining of mature myeloid cells of controls. The mature 
myeloid cells were diminished in 5’UTRnipblb-MO injected embryos (I) in comparison to controls 
(H); quantification of the observed phenotypes in (J). (K) Quantification of embryos with increased 
number of myeloid precursor cells positive for spi1b. The co-injection of subcritical doses of the two 
morpholinos against niplbl, but not that of the single morpholino, recapitulated the myeloid 
phenotype observed with the injection of morpholino full doses. Scale bar represents 100 m. 
Asterisks in (G, J, K) represent ***=p<0.001. ns: non-significant; UTR: UnTranslated Region; 
WISH: Whole Mount In Situ Hybridization; MO: morpholino; HSCs: Hematopoietic Stem Cells; RT: 
Retro Transcription. 
 
 
Suppl. Figure S5: Validation of inhibition of canonical Wnt pathway by means of dkk1b mRNA 
injection in the zebrafish Wnt reporter line TOPdGFP. (A-D) Confocal images of TOPdGFP 
zebrafish embryos at 3 dpf. The GFP+ cells in the hindbrain (h, arrow) and in the eye of controls (A), 
were not present in dkk1b mRNA injected embryos (B). (C-D) Also in the CHT region, the GPF+ 
cells were absent in dkk1b injected embryos (D) in comparison to controls (C) (arrows). Scale bar 
represents 100 m. GFP: Green Fluorescent Protein; CHT: Caudal Hematopoietic Tissue. 
 
 
Suppl Figure S6: Different canonical Wnt pathway modulation during zebrafish development 
following nipblb downregulation. (A-H) analysis of canonical Wnt pathway activation at 24 hpf in 
nipblb-loss-of-function zebrafish embryos. (A) Image of a 24 hpf embryo, the head region was 
selected for confocal images in (B-C). The GFP expression in the Central Nervous System of 
TOPdGFP nipblb-MO injected embryos (C) was decreased in comparison to controls (B). (D) Image 
of a 24 hpf embryo, the Aorta Gonad Mesonephric (AGM) tissue was selected for confocal images 
in (E-F’). The GFP expression of Wnt positive cells in AGM of controls (E-E’) and nipblb-MO 
injected embryos (F-F’) was indistinguishable from blood cells autofluorescence at this 
developmental stages. (G) Western blot analyses confirmed the GFP protein reduction in 24 hpf 
nipblb-MO injected embryos in comparison to controls. Vinculin was used as normalizer. (H) RT-
qPCR analyses of axin2 expression, a marker of the status of canonical Wnt pathway. A representative 
experiment was shown. (I-L) Analyses of canonical Wnt pathway activation at 48 hpf. (I-J) The GFP 
expression in the CHT of TOPdGFP nipblb-MO injected embryos (J) was increased in comparison 
to controls (I). (K) Western blot analyses confirmed the GFP protein increase in 48 hpf nipblb-MO 
injected embryos at in comparison to controls. Vinculin was used as normalizer. (L) RT-qPCR 
analyses of axin2 expression, a marker of the status of canonical Wnt. DAPI staining was used in B, 
C, E’, F’. A representative experiment was shown. Scale bars represent 100 m. RT-qPCR and 
Western blot experiment were replicated twice and the data in the figure are the average of the two 
different experiments. MO: morpholino; GFP: Green Fluorescent Protein; CHT: Caudal 
Hematopoietic Tissue; RT: Retro Transcription. 
 
 
Suppl. Figure S7: AXIN2 increased expression in AML patients with NIPBL downregulation. 
RT-qPCR analyses of AXIN2 expression in N=40 AML adult patients divided in two subgroups 
depending on NIPBL expression: NIPBL>1 and NIPBL<1 in comparison to healthy donors. We did 
not observe a significant increase in AXIN2 expression when NIPBL was downregulated. ns: non-
significant; RT: Retro Transcription. 
 
 
Suppl. Table S1 
 
 
 
 
 
Supplementary	Table	S1.	Clinical	Features	of	patients'	cohort.
AGE	AT	ONSET KARYOTYPE FAB	CLASSIFICATION NPM FLT3-ITD t(9;22) t(8;21) 	inv(16)
1 47 46,XX,t(10;11)(p11;p15)[20] M0 NEG NEG NEG NEG NEG
2 49 46,XY[20] M0/M1 NEG NEG NEG NEG NEG
3 48 46,XX[20] M1 NEG NEG NEG NEG NEG
4 70 45,X,-Y,t(8;21)(q22;q22)[5]/46,XY[5] M2 NEG NEG NEG NEG NEG
5 72 47,XY,+mar[10]/46,XY[10] M2 NEG NEG NEG NEG NEG
6 58 46,XX,t(3;5)(q25;q34)[20] M2 NEG NEG NEG NEG NEG
7 70
44~45,XX,?+X,t(1;22)(q12;q11),+1,del(5)(q13q34),?inv(7)(q14q22),tas(8;15)(q24;p13),-17,-
21,del(22)(q11)der(22)t(1;22)(q12;q11),+mar[cp18]/45,XX,t(1;22)(q12;q11),+1,del(5)(q13q34),-
7,der(17)t(7;17)(q11;q25),-21,del(22)(q11)der(22)t(1;22)(q12;q11)[7]
M4 NEG NEG NEG NEG NEG
8 48 45,X,-X,t(8;21)(q22;q22)[20]/45,X,-X[3] M2 NEG NEG POS NEG NEG
9 47 45-46,XY,del(3)(q?22q?26),der(4)t(?1;4)(p36;p16),add(11)(p14),-12,del(12)(p11),add(21)(q22)[cp13]/46,XY[7] nk NEG NEG nk NEG NEG
10 37 43,XY,?del(2)(q?33),-4,der(6)t(?4;6)(q?22;q21),i(11)(q10),-17,-18[19]/46,XY[2] M1 NEG NEG NEG nk nk
11 59 46,XY[20] nk NEG POS NEG NEG NEG
12 33 46,XY[15] M1 NEG POS NEG NEG NEG
13 30 46,XY[20] M5 NEG POS nk NEG NEG
14 20 46,XY,t(8;21)(q22;q22)[21]/46,XY[1] nk NEG POS nk POS NEG
15 58 46,XY,inv(16)(p13q22)[20] M4 NEG POS nk POS NEG
16 76 nk M5 NEG POS nk NEG NEG
17 78 46,XX[27] M4 NEG POS nk NEG NEG
18 53 46,XY[22] M4 NEG POS nk NEG NEG
19 64 46,XX[20] M5 NEG POS nk NEG NEG
20 75 46,XY[26] M4 NEG POS nk NEG NEG
21 39 46,XY[20] M1 POS	(A) NEG NEG NEG NEG
22 47 46,XX[20] M5 POS	(A) NEG NEG NEG NEG
23 63 46,XY,t(8;14)(q24;q32),add(13q34)[18]/46,XY[9] nk POS	(D) NEG nk NEG NEG
24 58 46,XY/47,XY,+8[7/10] nk POS	(QM) NEG nk NEG NEG
25 50 46,XX[20] M4 POS	(A) NEG nk NEG NEG
26 77 46,XY[20] nk POS	(A) NEG nk NEG NEG
27 54 46,XX,t(9;22)(q34;q11)[14]/46,XX[6] M4 POS	(A) NEG POS NEG NEG
28 60 46,XX[6] nk POS NEG nk NEG NEG
29 62 46,XX[25] M5 POS	(A)
NEG	ITD/POS	
D835/D836
nk NEG NEG
30 58 46,XX[20] nk POS	(A) NEG nk NEG NEG
31 48 46,XX[20] M4 POS	(A) POS NEG NEG NEG
32 51 46,XX[20] M5 POS	(A) POS NEG NEG NEG
33 68 46,XX[20] M4 POS	(A)
POS	ITD/POS	
D835/D836
NEG NEG NEG
34 46 46,XY[20] M2 POS POS NEG NEG NEG
35 39 46,XX[22] M1 POS	(A) POS nk NEG NEG
36 58 46,XY M5 POS	(A) POS nk NEG NEG
37 35 46,XY,?r(18)(?)[16]/47,idem,+8[3]/46,XY[1] nk POS	(B) POS nk NEG NEG
38 58 46,XY[24] M1 POS	(A) POS nk NEG NEG
39 70 46,XY[20] M5 POS	(A) POS nk NEG NEG
40 12 46,XY[24] nk POS	(A) POS NEG NEG NEG
Suppl. Table S2 
Human primers sequence and probe number used in qPCR experiments. 
PRIMER lenght sequence PROBE 
hGUS-L 20 CGCCCTGCCTATCTGTATTC 57 
hGUS-R 20 TCCCCACAGGGAGTGTGTAG   
hNIPBL-L 19 CTATGCGAACAGCCCAAAA 55 
hNIPBL-R 24 TTCACCTTGCTTACTACCACATTT   
hSMC1A-L 21 CGACATCTAGCCCTGAATCTG 78 
hSMC1A-R 20 ATTAATGCGAGGCCCAAAGT   
hRAD21-L 20 ATTGACCCAGAGCCTGTGAT 62 
hRAD21-R 20 GGGGAAGCTCTACAGGTGGT   
hSMC3-L 22 TGCACTGAATGATGAGATTCGT  18 
hSMC3-L 27 TTAATTCTTTCATTTAGCAACTGTCTG    
hAXIN2-L 19 CCACACCCTTCTCCAATCC 36 
hAXIN2-R 20 TGCCAGTTTCTTTGGCTCTT  
 
 
 
Suppl. Table S3 
Zebrafish primers sequence used in qPCR 
experiments. 
PRIMER lenght sequence 
zrpl8-L 21 CTCCGTCTTCAAAGACCATGT 
zrpl8-R 21 TCCTTCACGATCCCCTTGATG 
znipblb-L 20 TGGAAGAAAAGACTCCTGGG 
znipblb-R 20 ACGTCCGTGGCTTCCACGGT 
zsmc1a-L 20 AAATGTGGAGGACGCTCGTA 
zsmc1a-R 20 AGGTCACTAGCTCCTCCAGA 
zrad21-L 20 AGGAAGGACAGGGAGGAGAT 
zrad21-R 20 GTTGTTTCTGCACAGCTCCA 
zsmc3-L 20 CCCTTCGGCTCAAAACACAA 
zsmc3-R 20 TGGCCGAAGATGACTGAACT 
 zspi1b-L  19 GCCATTTCATGGACCCAGG 
 zspi1b-R  19 ACACCGATGTCCGGGGCAA 
 zcmyb-L  20 GACACAAAGCTGCCCAGTTG 
 zcmyb-R  20 GCTCTTCCGTCTTCCCACAA 
 zaxin2-F  20 GGCCACTGTAGTGGGTCTGT 
 zaxin2-R  20 ATTAGGATTTCCGGGGTCAC 
 
 
Suppl. Table S4 
 
 
 
 
 
Antibodies  Specie Concentration Technique 
Vinculin mouse 1:6000 WB 
NIPBL rabbit 1:200 WB 
Active-cat mouse 1:50 IF 
Pu.1 rabbit 1:100 IF/FACS 
Alexa anti mouse 546 goat 1:400 IF 
